Clot Risk of Lilly’s Lung Cancer Drug Raises Concerns at FDA
This article is for subscribers only.
Eli Lilly & Co.’s experimental lung cancer drug raised concerns with U.S. regulators that it may increase patients’ risk of suffering potentially deadly blood clots.
The drug, known as necitumumab, improved patients’ overall chances of survival, yet people taking the medicine also experienced more risk, Food and Drug Administration staff said in a report Tuesday. Lilly is seeking to sell the medicine to treat a subset of the most common type of lung cancer.